Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Date:1/4/2012

SAN FRANCISCO, Jan. 4, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 30th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Wednesday, January 11, 2012 at 8:30 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 12, 2012.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled seven approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. Nektar has an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects. NKTR-181, a novel mu-opioid analgesic, has completed
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Therapeutics to Webcast R&D Day on November 12th
5. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Retirement of Irwin Lerner from Board of Directors
8. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... ... global failure analysis market is expected to reach $7,147.0 million by 2020, at a ... at the highest CAGR of 8.46%; its growth is expected to be driven by ... for root cause analysis of failure. The market based on the geographic regions has ...
(Date:7/3/2015)... 3, 2015 Forskere ... 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab ... sted i Wien .  ... internationale forskere og videnskabsmænd foretaget af Ludwig ... udfordringer for sundhedsvidenskaben manglen på incitamenter til ...
(Date:7/2/2015)... , July 2, 2015 Amici ... Bio-tech procurement company Amici Procurement has chosen Microsoft Cloud ... it move to Office 365.      (Logo: ... small to medium-sized companies in the bio-tech sector with ... of the purchasing cycle to help them obtain best ...
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
Breaking Biology Technology:Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Biotech Procurement Company Moves to Office 365 with iomart 2AgBiome and Genective collaborate to create novel insect-resistant crops 2
... In biological research laboratories, filtration techniques are performed to ... buffers, and separate and purify samples for processing. In most cases, ... , The majority of filtration ... to 50 Torr (25 28Hg). A number of plastic ...
... , Overview: ... in analyzing the proteome of human serum is the dynamic range of ... (HSA) constitutes 57-71% of total serum protein and gammaimmunoglobulin (IgG) ranges from ... total protein present in serum, thereby allowing the enhanced detection of the ...
... Overview , ... has been used very little for quantitative studies. Analysts ... between analyte and internal standards and an inherent heterogeneity ... as a quantitative technique. In addition, conventional MALDI-TOF spectral ...
Cached Biology Technology: Improving the Efficiency of Common Filtration Tasks in your Laboratory 2 Improving the Efficiency of Common Filtration Tasks in your Laboratory 3Affinity Depletion Cartridges for Removal of Human Serum Albumin and Immunoglobulins from Human Serum 2Affinity Depletion Cartridges for Removal of Human Serum Albumin and Immunoglobulins from Human Serum 3Affinity Depletion Cartridges for Removal of Human Serum Albumin and Immunoglobulins from Human Serum 4Affinity Depletion Cartridges for Removal of Human Serum Albumin and Immunoglobulins from Human Serum 5Small-Molecule Quantitation Using Automated Single-Shot Averaging MALDI-TOF Mass Spectrometry 2Small-Molecule Quantitation Using Automated Single-Shot Averaging MALDI-TOF Mass Spectrometry 3
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... implications for improving fertilization in humans and other mammals, ... in red abalone, an ocean-dwelling snail, and made precise ... are the first scientists to do so. ... in the laboratory, the scientists were able to determine ...
... Calif., August 14, 2011 Newly diagnosed type 2 ... Exactly how diet and obesity trigger diabetes has long ... study led by Jamey D. Marth, Ph.D., director of ... of California, Santa Barbara and Sanford-Burnham Medical Research Institute ...
... VILNIUS, Lithuania, July 6, 2011 Neurotechnology ... today introduced VeriSpeak , the company,s new ... the VeriSpeak Software Development Kit (SDK) and as ... MegaMatcher 4.1 multi-biometric SDK, also announced today. VeriSpeak ...
Cached Biology News:UCLA life scientists' study of abalone yields new insights into sexual reproduction 2UCLA life scientists' study of abalone yields new insights into sexual reproduction 3UCLA life scientists' study of abalone yields new insights into sexual reproduction 4How fatty diets cause diabetes 2Neurotechnology Introduces VeriSpeak Voice Identification Technology 2Neurotechnology Introduces VeriSpeak Voice Identification Technology 3Neurotechnology Introduces VeriSpeak Voice Identification Technology 4